Hypoglycemia is a common adverse event in patients with both type 1 and type 2 diabetes and may be a barrier to patients achieving tight glycemic control. It is diagnosed either biochemically, as a blood glucose value, or clinically based on symptoms caused by an autonomic response to changes in blood glucose. Patients that experience repeated episodes of hypoglycemia lose the counterregulatory response that produces symptoms and results in hypoglycemia unawareness. Medications account for the most frequent cause of hypoglycemia in both the inpatient and outpatient setting. Treatment of hypoglycemia may be accomplished via the oral or parenteral route with 15 to 20 g of carbohydrate. Following treatment of the episode, it is important to evaluate for the cause and, if medication related, adjust the patient’s treatment regimen.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.
2.
UKPDS Research Group. Effort of intensive blood glucose control with insulin and sulfonylureas on insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–885.
3.
AbrairaCColwellJANuttallFQ. Veterans Affairs Cooperative Study on glycemia control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care. 1995;18:1113–1123.
4.
American Diabetes Association. Standard of medical care in diabetes. Diabetes Care. 2008;31:S12–S54.
5.
American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus. Endocr Pract. 2007;13:3–68.
6.
CryerPE. Hypoglycemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002;45:937–948.
7.
PrammingSThorsteinssonBBendtsonI. Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabet Med. 1991;8:217–222.
8.
GuettierJGordenP. Hypoglycemia. Endocrinol Metab Clin N Am. 2006;35:755–766.
9.
van den BerghGWoutersPWeekersF. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359–1367.
10.
The UKPDS Research Group. Overview of 6 years of therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–1258.
11.
ServiceFJDaleAjdElvebackLR. Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc. 1976;51:417–429.
12.
BondsDEKurashigeEMBergenstalR. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Am J Cardiol. 2007;99:80i–89i.
13.
HoffmanRP. Sympathetic mechanisms of hypoglycemia counterregulation. Curr Diab Rev. 2007;3:185–193.
FanelliCGPorcellatiFPmpanelliS. Insulin therapy and hypoglycaemia: the size of the problem. Diabetes Metab Res Rev. 2004;20(Suppl 2):S32–S42.
17.
CryerPEDavisSNShamoonH. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902–1912.
18.
HellerSRCryerPE. Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans. Diabetes. 1991;40:223–226.
19.
Dagogo-JackSECraftSCryerPE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest. 1993;91:819–828.
20.
CryerPE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002;45:937–948.
21.
GuettierJMGordenP. Hypoglycemia. Endocrinol Metab Clin N Am. 2006;35:753–766.
22.
Ben-AmiHaimNagachandranPMendelsonA. Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Int Med. 1999;159:281–284.
23.
Carroll MaryFBurge MarkRSchade DavidS. Severe hypoglycemia in adults. Rev Endocr Metab Disord. 2003;4:149–157.
24.
Rowden AdamKFasano CharlesJ. Emergency management of oral hypoglycemic drug toxicity. Emerg Med Clin North Am. 2007;25(2):347–356.
25.
Malaisse WillyJ. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol. 2003;2:401–414.
26.
Pandit ManjulaKBurkeJGustafsonAB. Drug-induced disorders of glucose tolerance. Ann Intern Med. 1993;118:529–539.
27.
Glucose Abnormalities and Fluoroquinolones—An Update. Pharmacist’s Letter/Prescriber’s Letter2006;22:220–315
28.
Lewis RoshanJMohr JohnFIII. Dysglycaemias and fluoroquinolones. Drug Safety. 2008;31:283–292.
29.
DyerJRDavisTMGieleC. The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly. Br J Clin Pharmacol. 1994;28:205–212.
30.
Vriesendorp TitiaMvan SantenSDeVriesJH. Predisposing factors for hypoglycemia in the intensive care unit. Crit Care Med. 2006;34:96–101.
31.
BoylePJZrebiecJ. Management of diabetes-related hypoglycemia. S Med J. 2007;100:183–194.
